Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorRoswell Park Cancer Institute

About this trial

\*As of June 2026- Phase I has been completed and we are now in Phase II. This phase I/II trial studies the side effects and how well fluorescence image guided surgery followed by intraoperative photodynamic therapy for improving local tumor control in patients with colorectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has come back after a period of improvement (recurrent). Fluorescence image guided surgery uses a drug named aminolevulinic acid hydrochloride. Aminolevulinic acid hydrochloride is a photosensitizing agent, meaning that is activated by light and, is converted to another drug in cancer cells more than in normal cells. The converted drug emits fluorescence red light when activated with low power blue light. It is used to assist the surgeon to see cancer cells and small cancerous tissue that may have been missed during routine surgery. In addition to emitting fluorescence light, the converted drug in the cancer cells and tissue can be activated with red laser light to kill cancer cells. This procedure is called photodynamic therapy (PDT). Performing fluorescence image guided surgery followed by intraoperative photodynamic therapy after the surgical removal of the colorectal tumor before the surgical site will be closed may be effective and improve outcomes in patients with locally advanced or recurrent colorectal cancer.

Eligibility criteria

Qualifiers

Age ≥ 18 years of age

Patients with locally advanced or recurrent colorectal cancer undergoing surgery

Amenable to diagnostic CT and MR imaging

Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3

Disqualifiers

Pregnant or nursing female participants

Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive the fluorescence-guided surgery with intraoperative PDT

Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds

Patients who are not cleared to undergo surgery

Trial design

Treatments tested in this trial

  • Aminolevulinic Acid
  • Biospecimen Collection
  • Computed Tomography
  • Fluorescence-Guided Surgery
  • Magnetic Resonance Imaging
  • Photodynamic Therapy
  • Surgical Procedure

Treatment groups

21 Participants
are divided into 1 treatment group

Sponsors and collaborators

Roswell Park Cancer Institute

Lead sponsor

National Center for Advancing Translational Sciences (NCATS)

Collaborator